Table 2.
Clinical and demographic characteristics in the all-treated target population
| |
Telavancin |
Standard therapy |
Overall |
|---|---|---|---|
| (n = 15) | (n = 16) | (n = 31) | |
| Age in years (mean ± SD) |
59 ± 16.3 |
60 ± 20.4 |
60 ± 18.2 |
| Age ≥65 |
5 (33%) |
7 (44%) |
12 (39%) |
| Gender, male |
10 (67%) |
8 (50%) |
18 (58%) |
| Race, white |
11 (73%) |
10 (63%) |
21 (68%) |
| Body mass index ≥30 |
6 (40%) |
3 (19%) |
9 (29%) |
| Diabetes |
7 (47%) |
10 (63%) |
17 (55%) |
| Prior antimicrobial therapy
a
|
14 (93%) |
16 (100%) |
30 (97%) |
| Vancomycin |
13 (87%) |
14 (88%) |
27 (87%) |
| Primary source of bacteremia identified |
12 (80%) |
13 (81%) |
25 (81%) |
| IV catheter |
8 (53%) |
9 (56%) |
17 (55%) |
| Skin and soft tissue |
3 (20%) |
3 (19%) |
6 (19%) |
| Other |
1 (7%) |
1 (6%) |
2 (6%) |
| MRSA | 7 (47%) | 8 (50%) | 15 (48%) |
IV, intravenous; MRSA, methicillin-resistant Staphylococcus aureus.
a Within 7 days prior to initiation of study medication.